Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
An early PIVKA-II response is predictive of tumor response and superior survival outcomes in patients who received ICIs for advanced HCC.
Authors
- Chien-Huai Chuang
- Yu‐Yun Shao (ORCID: https://orcid.org/0000-0001-7334-1912)
- Ching-Tso Chen (ORCID: https://orcid.org/0000-0003-0116-9396)
- Chiun Hsu (ORCID: https://orcid.org/0000-0002-1122-0055)
Institutions
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/jhc.s548785
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministry of Health and Welfare
- National Science Council
- Ministry of Science and Technology, Taiwan
- National Taiwan University Hospital
- National Taiwan University
- National Science and Technology Council